Last reviewed · How we verify
FluLavalTM-VB
FluLaval-VB is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.
FluLaval-VB is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | FluLavalTM-VB |
|---|---|
| Also known as | FluLavalTM containing the Victoria B flu strain, FluLaval®-VB, Victoria Strain FluLaval vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated quadrivalent influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens from two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages. Upon administration, these antigens trigger both humoral (antibody) and cellular immune responses, priming the immune system to recognize and neutralize circulating influenza viruses during the flu season.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |